02/19/2019

Recent Oncology Related FDA Approvals/Changes

• FDA approved pembrolizumab (KEYTRUDA, Merck) for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. More Information.  February 15, 2019 (1)

• FDA approved ibrutinib (IMBRUVICA) in combination with obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), the most common form of leukemia in adults. More Information.  January 28, 2019 (2)

• FDA approved a new indication for pemetrexed (Alimta) for injection in combination with pembrolizumab (Keytruda) and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.. More Information.  January 31, 2019 (2)